COOP vs. KRYS

Last updated Jun 3, 2026

COOP (Mr. Cooper Group Inc.) and KRYS (Krystal Biotech, Inc.) are both stocks. COOP operates in Mortgage Finance (Financial Services), while KRYS operates in Biotechnology (Healthcare). At a 0.22 correlation, their price movements are largely independent.

Performance

COOP vs. KRYS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Mr. Cooper Group Inc. (COOP) and Krystal Biotech, Inc. (KRYS). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

COOP

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

KRYS

• 1D: -1.64%
• 1M: 10.21%
• YTD: 18.93%
• 6M: 36.34%
• 1Y: 133.89%
• 3Y*: 33.15%
• 5Y*: 36.38%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

COOP vs. KRYS - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
COOP Mr. Cooper Group Inc.	0.00%	121.64%	47.44%	62.27%	-3.56%	34.10%	148.04%	7.20%	14.53%	-22.81%
KRYS Krystal Biotech, Inc.	18.93%	57.37%	26.28%	56.60%	13.25%	16.58%	8.34%	166.51%	97.53%	-1.13%

Correlation

The correlation between COOP and KRYS is 0.14, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.14
Correlation (3Y) Calculated over the trailing 3-year period	0.26
Correlation (5Y) Calculated over the trailing 5-year period	0.25
Correlation (All Time) Calculated using the full available price history since Sep 21, 2017	0.22

The correlation between COOP and KRYS shifts across timeframes, from 0.14 (1 year) to 0.26 (3 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap COOP : $13.72B KRYS : $8.94B
EPS COOP : $8.76 KRYS : $7.50
PE Ratio COOP : 24.07 KRYS : 39.10
PEG Ratio COOP : 0.24 KRYS : 0.10
PS Ratio COOP : 6.00 KRYS : 21.09
PB Ratio COOP : 2.69 KRYS : 7.01
Total Revenue (TTM) COOP : $2.29B KRYS : $417.30M
Gross Profit (TTM) COOP : $1.68B KRYS : $387.24M
EBITDA (TTM) COOP : $852.00M KRYS : $185.45M

Return for Risk

COOP vs. KRYS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

KRYS

KRYS Risk / Return Rank: 95
KRYS Sharpe Ratio Rank: 96
KRYS Sortino Ratio Rank: 93
KRYS Omega Ratio Rank: 93
KRYS Calmar Ratio Rank: 96
KRYS Martin Ratio Rank: 96

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

COOP vs. KRYS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Mr. Cooper Group Inc. (COOP) and Krystal Biotech, Inc. (KRYS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	COOP	KRYS	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	3.46	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.48	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	0.63	—

Drawdowns

Drawdown Indicators

	COOP	KRYS	Difference
Max Drawdown Largest peak-to-trough decline	—	-53.42%	—
Max Drawdown (1Y) Largest decline over 1 year	—	-15.94%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-42.26%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-44.55%	—
Current Drawdown Current decline from peak	—	-7.30%	—
Average Drawdown Average peak-to-trough decline	—	-16.22%	—
Ulcer Index Depth and duration of drawdowns from previous peaks	—	6.13%	—

Volatility

Volatility by Period

	COOP	KRYS	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	12.37%	—
Volatility (6M) Calculated over the trailing 6-month period	—	27.11%	—
Volatility (1Y) Calculated over the trailing 1-year period	—	38.96%	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	—	76.43%	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	—	74.25%	—

Dividends

COOP vs. KRYS - Dividend Comparison

COOP's dividend yield for the trailing twelve months is around 0.95%, while KRYS has not paid dividends to shareholders.

Position	TTM	2025
COOP Mr. Cooper Group Inc.	0.95%	0.95%
KRYS Krystal Biotech, Inc.	0.00%	0.00%

Financials

COOP vs. KRYS - Profitability Comparison

The chart below illustrates the profitability comparison between Mr. Cooper Group Inc. and Krystal Biotech, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

COOP - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Mr. Cooper Group Inc. reported a gross profit of 417.00M and revenue of 608.00M. Therefore, the gross margin over that period was 68.6%.

KRYS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Krystal Biotech, Inc. reported a gross profit of 110.03M and revenue of 116.36M. Therefore, the gross margin over that period was 94.6%.

COOP - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Mr. Cooper Group Inc. reported an operating income of 293.00M and revenue of 608.00M, resulting in an operating margin of 48.2%.

KRYS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Krystal Biotech, Inc. reported an operating income of 53.69M and revenue of 116.36M, resulting in an operating margin of 46.1%.

COOP - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Mr. Cooper Group Inc. reported a net income of 198.00M and revenue of 608.00M, resulting in a net margin of 32.6%.

KRYS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Krystal Biotech, Inc. reported a net income of 55.93M and revenue of 116.36M, resulting in a net margin of 48.1%.

Frequently Asked Questions

Can I hold both COOP and KRYS in my portfolio?

COOP and KRYS have a correlation of 0.14, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.